ClinicalTrials.gg
CompletedNCT05042440Updated Sep 18, 2025

Pharmacokinetic Assessment of Standard Half-Life (SHL) FVIII, Extended Half-Life (EHL) FVIII, and Efanesoctocog Alfa (BIVV001) in Severe Hemophilia A

A Phase 1 interventional study of Efanesoctocog alfa and Octocog alfa in Hemophilia A, sponsored by Sanofi. Completed at 1 site in Bulgaria. Open to male participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-09-18.

Sponsored by Sanofi · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
13
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing efanesoctocog alfa in Hemophilia A — 1 open to participants now, 5 under way, 2 of them phase 3. efanesoctocog alfa · Hemophilia A.

Enrollment
11th of 11
13 · median 74
Started
2021
with 2 others
Phase 1
2 of 11
none open now
Registered
5th of 11
by date
Lead sponsor
2 of 11
Sanofi

Among the 11 studies testing efanesoctocog alfa in Hemophilia A, this one is the 11th largest by enrollment, is one of 3 that started in 2021, is one of 2 in phase 1, and was the 5th registered.

Hemophilia A

844 studies on the registry are indexed under Hemophilia A; 136 are open to participants now.

Browse Hemophilia A studies →

Open to participants now

1 of the 11 studies testing efanesoctocog alfa in Hemophilia A is open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

About efanesoctocog alfa

efanesoctocog alfa: first FDA approval 2023 (ALTUVIIIO), first EMA approval 2024. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 87 Hemophilia A studies recruiting now, 51 (59%) set no upper age limit and 31 (36%) stop at 75 or younger; 55 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 65 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing efanesoctocog alfa in Hemophilia A, or all of them as a file.
02

Study summary

Primary objective

  • To assess the half-life of BIVV001, Standard Half-Life (SHL) rFVIII and Extended Half-Life (EHL) rFVIII after a single intravenous (IV) injection

Secondary objectives

  • To characterize additional pharmacokinetic (PK) parameters of BIVV001, SHL rFVIII and EHL rFVIII after a single IV injection
  • To evaluate the safety and tolerability of a single IV injection of BIVV001
Read the detailed description

This is a Phase 1, single center, open-label, sequential treatment, 3-period fixed sequence study to assess PK profiles of BIVV001, SHL and EHL rFVIII after a single IV injection in male, previously treated patients, 18-65 years of age, with severe hemophilia A (defined as \<1 IU/dL [\<1%] endogenous FVIII).

The expected duration of the study is up to approximately 67 days including

  • Screening and washout up to 28 days,
  • Advate® dosing, PK sampling, including washout: approximately 4 days,
  • Adynovi® dosing and PK sampling, including washout: approximately 7 days,
  • BIVV001 dosing and PK sampling: approximately 14 days, Remainder of Safety Observation Period: approximately 14 days.
03

Conditions studied

  • Hemophilia A

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Severe hemophilia A, defined as \<1 IU/dL (\<1%) endogenous FVIII activity.
  • Previous treatment for hemophilia A, defined as at least 150 days documented prior exposure to any recombinant and/or plasma-derived FVIII and/or cryoprecipitate products at Day 1.
  • count ≥100,000 cells/µL at Screening.
  • A participant known to be (HIV) antibody positive, either previously documented or identified from screening assessments, must have the following results prior to enrollment. ( >200 cells/mm³ - Viral load of \<400 copies/mL).

Exclusion criteria

Exclusion Criteria:

  • Any concurrent liver disease that, in the opinion of the Investigator, would make the participant unsuitable for enrollment. This may include, but is not limited to cirrhosis, portal hypertension, and acute hepatitis.
  • Serious active bacterial, fungal or viral infection (other than chronic hepatitis or ) present within 30 days of Screening.
  • Other known coagulation disorder(s) in addition to hemophilia A.
  • History of or anaphylaxis associated with any FVIII product.
  • History of a positive inhibitor test defined as ≥0.6 BU/mL, or any value greater than or equal to the lower sensitivity cut-off for laboratories with cut-offs for inhibitor detection between 0.7 and 1.0 BU/mL, or clinical signs or symptoms of decreased response to FVIII administrations. Family history of inhibitors will not exclude the participant.
  • Positive inhibitor result, defined as ≥0.6 BU/mL at Screening.
  • Major surgery within 8 weeks of Screening.
  • Sensitivity to any of the study interventions, or components thereof, or drug or other allergy.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
13 participants (actual)

Study arms

  • Experimental
    efanesoctocog alfa (BIVV001)

    Each participant will be sequentially dosed with three single intravenous (IV) doses of first rFVIII (Advate®), second Polyethylene Glycol (PEG)-rFVIII (Adynovi® or Adynovate®), and lastly, BIVV001

    Drug: Efanesoctocog alfa · Drug: Octocog alfa · Drug: Rurioctocog alfa pegol

Interventions

06

What researchers measure

Primary outcomes

  1. Half-life of BIVV001

    Time frame: BIVV001 period: Predose, and post-dose from 0.17 hr to 336 hr, and at day 28

  2. Half-life of SHL rFVIII

    Time frame: Advate® period: Predose, and post-dose from 0.17 hr to 72 hr

  3. Half-Life of EHL rFVIII

    Time frame: Adynovi® period: Predose, and post-dose from 0.17 hr to 120 hr

Secondary outcomes

  1. Assessment of pharmacokinetic (PK) parameter : maximum activity (Cmax)

    Time frame: Predose of each period, 0.17 hr to 72 hr for Advate® ; 0.17 hr to 120 hr for Adynovi® ; 0.17 hr to 336 hr and at day 28 for BIVV001

  2. Assessment of PK parameter : clearance (CL)

    Time frame: Predose of each period, 0.17 hr to 72 hr for Advate® ; 0.17 hr to 120 hr for Adynovi® ; 0.17 hr to 336 hr and at day 28 for BIVV001

  3. Assessment of PK parameter : volume of distribution at steady state (Vss)

    Time frame: Predose of each period, 0.17 hr to 72 hr for Advate® ; 0.17 hr to 120 hr for Adynovi® ; 0.17 hr to 336 hr and at day 28 for BIVV001

  4. Assessment of PK parameter : area under the activity time curve extrapolated to infinity (AUC∞)

    Time frame: Predose of each period, 0.17 hr to 72 hr for Advate® ; 0.17 hr to 120 hr for Adynovi® ; 0.17 hr to 336 hr and at day 28 for BIVV001

  5. Assessment of PK parameter : mean residence time (MRT)

    Time frame: Predose of each period, 0.17 hr to 72 hr for Advate® ; 0.17 hr to 120 hr for Adynovi® ; 0.17 hr to 336 hr and at day 28 for BIVV001

  6. Assessment of PK parameter : incremental recovery (IR)

    Time frame: Predose of each period, 0.17 hr to 72 hr for Advate® ; 0.17 hr to 120 hr for Adynovi® ; 0.17 hr to 336 hr and at day 28 for BIVV001

  7. Number of participants with Adverse events (AE), serious AEs and treatment-emergent AEs (TEAEs)

    Time frame: From Day 1 up to 28 days after administration of BIVV001 (total 39 days including Advate® and Adynovi® period)

  8. Development of inhibitors (neutralizing antibodies directed against FVIII)

    Number of participants with development of inhibitors

    Time frame: Advate® period: Pre-dose; Adynovi® period: Pre-dose; BIVV001 period: Pre-dose and at day 14 and 28 after administration.

07

Study locations

1 site
  • Investigational Site Number :1000001
    Sofia, 1756, Bulgaria
08

References and documents

Publications

  • Lissitchkov T, Willemze A, Jan C, Zilberstein M, Katragadda S. Pharmacokinetics of recombinant factor VIII in adults with severe hemophilia A: fixed-sequence single-dose study of octocog alfa, rurioctocog alfa pegol, and efanesoctocog alfa. Res Pract Thromb Haemost. 2023 May 13;7(4):100176. doi: 10.1016/j.rpth.2023.100176. eCollection 2023 May. PubMed 37538505 ↗

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2021 to primary completion in Nov 2021, 3 months.

Of 37 industry-sponsored phase 1 interventional studies under Hemophilia A, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 18. This study's 3 months is below that.

Counting every sponsor, half of 46 studies reached it within 13 months; a quarter within 7 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 12, 2021
First posted
Sep 13, 2021
StartActual
Aug 11, 2021
Primary completionActual
Nov 24, 2021
CompletionActual
Nov 24, 2021
Last update
Sep 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05042440
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Sep 13, 2021
Start date
Aug 11, 2021
Primary completion
Nov 24, 2021
Completion
Nov 24, 2021
Last update
Sep 18, 2025

Study contacts

Clinical Sciences and Operations
study director · Sanofi

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Efanesoctocog alfa

Start the discussion